Search research articles
Contact Us
Filters
Showing results (51-60 of 80) with videos related to
Page
of 8
Sort By:
Klinische Wochenschrift
|
April 2, 1990
[Terguride in hyperprolactinemia--experiences with 5 patients]
C Wüster, A Scholz, A Schmelzle, et al.
Headache
|
May 1, 1977
Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide
W M Herrmann, R Horowski, K Dannehl, et al.
Neurology
|
March 1, 1995
An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient
R Horowski, L Horowski, S Vogel, et al.
Life Sciences
|
November 29, 2005
Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: interactions with alpha(1)-, 5-HT(2)- and H(1)-receptors
B Schurad, R Horowski, S Jähnichen, et al.
Acta Neurologica Scandinavica
|
June 1, 1991
Lisuride plus selegiline in the treatment of early Parkinson's disease
G Nappi, E Martignoni, R Horowski, et al.
Acta Endocrinologica
|
September 1, 1979
Suppression of prolactin secretion by lisuride throughout the menstrual cycle and in hyperprolactinaemic menstrual disorders
H G Bohnet, J P Hanker, R Horowski, et al.
Nuklearmedizin. Nuclear Medicine
|
August 1, 1991
[A preclinical study of the organ distribution and radiation dosage of radioiodinated iodolisuride]
K Buchali, H Flade, B Johannsen, et al.
Clinical Neuropharmacology
|
October 1, 1989
A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain
G Micieli, E Martignoni, G Bono, et al.
Clinical Neuropharmacology
|
October 1, 1991
Antagonist effect of terguride in Parkinson's disease
S Ruggieri, F Stocchi, F Baronti, et al.
Functional Neurology
|
November 1, 1996
Lisuride and bromocryptine in L-Dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects
G Micieli, E Martignoni, A Cavallini, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 80) with videos related to
Sort By:
Page
of 8
Klinische Wochenschrift
|
April 2, 1990
[Terguride in hyperprolactinemia--experiences with 5 patients]
C Wüster, A Scholz, A Schmelzle, et al.
Headache
|
May 1, 1977
Clinical effectiveness of lisuride hydrogen maleate: a double-blind trial versus methysergide
W M Herrmann, R Horowski, K Dannehl, et al.
Neurology
|
March 1, 1995
An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient
R Horowski, L Horowski, S Vogel, et al.
Life Sciences
|
November 29, 2005
Proterguride, a highly potent dopamine receptor agonist promising for transdermal administration in Parkinson's disease: interactions with alpha(1)-, 5-HT(2)- and H(1)-receptors
B Schurad, R Horowski, S Jähnichen, et al.
Acta Neurologica Scandinavica
|
June 1, 1991
Lisuride plus selegiline in the treatment of early Parkinson's disease
G Nappi, E Martignoni, R Horowski, et al.
Acta Endocrinologica
|
September 1, 1979
Suppression of prolactin secretion by lisuride throughout the menstrual cycle and in hyperprolactinaemic menstrual disorders
H G Bohnet, J P Hanker, R Horowski, et al.
Nuklearmedizin. Nuclear Medicine
|
August 1, 1991
[A preclinical study of the organ distribution and radiation dosage of radioiodinated iodolisuride]
K Buchali, H Flade, B Johannsen, et al.
Clinical Neuropharmacology
|
October 1, 1989
A study of the cardiopressor effects of lisuride in the treatment of parkinsonism and pathological aging brain
G Micieli, E Martignoni, G Bono, et al.
Clinical Neuropharmacology
|
October 1, 1991
Antagonist effect of terguride in Parkinson's disease
S Ruggieri, F Stocchi, F Baronti, et al.
Functional Neurology
|
November 1, 1996
Lisuride and bromocryptine in L-Dopa stable-responder parkinsonian patients: a comparative, double-blind evaluation of cardiopressor and neurochemical effects
G Micieli, E Martignoni, A Cavallini, et al.
Page
of 8